RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Dual-Targeting CAR t therapy takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial tests a new treatment called BMS-986453 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two proteins on cancer cells, to attack the disease. The s…
Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Wearable device could simplify multiple myeloma treatment
Disease control Recruiting nowThis study tests a new method of giving the drug isatuximab (Sarclisa) under the skin using a wearable device, combined with two other drugs (carfilzomib and dexamethasone), in 64 adults with multiple myeloma that has returned or not responded to prior therapy. The main goal is t…
Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC